"Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Descriptor ID |
D011658
|
MeSH Number(s) |
C08.381.765
|
Concept/Terms |
Pulmonary Fibrosis- Pulmonary Fibrosis
- Pulmonary Fibroses
- Fibroses, Pulmonary
- Fibrosis, Pulmonary
Alveolitis, Fibrosing- Alveolitis, Fibrosing
- Alveolitides, Fibrosing
- Fibrosing Alveolitides
- Fibrosing Alveolitis
- Hamman-Rich Syndrome
- Hamman Rich Syndrome
- Syndrome, Hamman-Rich
|
Below are MeSH descriptors whose meaning is more general than "Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Pulmonary Fibrosis".
This graph shows the total number of publications written about "Pulmonary Fibrosis" by people in this website by year, and whether "Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 0 | 2 |
1997 | 1 | 0 | 1 |
1998 | 1 | 1 | 2 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 3 | 0 | 3 |
2003 | 0 | 1 | 1 |
2004 | 4 | 0 | 4 |
2005 | 3 | 1 | 4 |
2006 | 4 | 2 | 6 |
2007 | 8 | 2 | 10 |
2008 | 4 | 1 | 5 |
2010 | 6 | 2 | 8 |
2011 | 2 | 3 | 5 |
2012 | 2 | 2 | 4 |
2013 | 4 | 1 | 5 |
2014 | 4 | 0 | 4 |
2015 | 2 | 1 | 3 |
2016 | 3 | 1 | 4 |
2017 | 4 | 0 | 4 |
2018 | 2 | 2 | 4 |
2019 | 7 | 1 | 8 |
2020 | 4 | 0 | 4 |
2021 | 3 | 0 | 3 |
2022 | 4 | 0 | 4 |
2023 | 3 | 0 | 3 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pulmonary Fibrosis" by people in Profiles.
-
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development? Eur Respir J. 2024 Feb; 63(2).
-
Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis. Ann Am Thorac Soc. 2023 12; 20(12):1683-1693.
-
ACSS3 regulates the metabolic homeostasis of epithelial cells and alleviates pulmonary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2024 02; 1870(2):166960.
-
Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023 01 15; 207(2):211-214.
-
Targeting Danger Signals to Rescue Fibrosis. Am J Respir Cell Mol Biol. 2022 05; 66(5):468-470.
-
Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Sci Rep. 2022 02 18; 12(1):2847.
-
Cadherin-11 Regulates Macrophage Development and Function. Front Immunol. 2022; 13:795337.
-
Lung fibrosis is induced in ADAR2 overexpressing mice via HuR-induced CTGF signaling. FASEB J. 2022 02; 36(2):e22143.
-
Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. Chest. 2022 04; 161(4):999-1010.
-
Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions. Respir Res. 2021 Apr 06; 22(1):99.